Mark Kagan

ORCID: 0009-0002-1776-0172
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Smoking Behavior and Cessation
  • Advanced Chemical Sensor Technologies
  • Pharmacogenetics and Drug Metabolism
  • Analytical Chemistry and Chromatography
  • Biochemical and Molecular Research
  • Toxic Organic Pollutants Impact
  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • Metabolomics and Mass Spectrometry Studies
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Carcinogens and Genotoxicity Assessment
  • Histone Deacetylase Inhibitors Research
  • Chronic Myeloid Leukemia Treatments
  • Biosimilars and Bioanalytical Methods
  • Antibiotics Pharmacokinetics and Efficacy
  • Mass Spectrometry Techniques and Applications
  • Fungal Plant Pathogen Control
  • Neuroscience of respiration and sleep
  • Lung Cancer Treatments and Mutations
  • Indoor Air Quality and Microbial Exposure
  • Chemical and Physical Properties in Aqueous Solutions
  • Liver Disease Diagnosis and Treatment
  • Sulfur Compounds in Biology
  • Lipid metabolism and disorders
  • Macrophage Migration Inhibitory Factor

Novartis (United States)
2021-2024

Tris Pharma (United States)
2024

Novartis (Switzerland)
2012-2021

Novartis Institutes for BioMedical Research
2021

Boston Biomedical Research Institute
2021

Bristol-Myers Squibb (Germany)
2018

Chugai Pharma (United States)
2018

Boehringer Ingelheim (Switzerland)
2018

Roche (Switzerland)
2018

Pfizer (United States)
2018

An analytical procedure was developed for the analysis of 1,3-butadiene, acrolein, isoprene, benzene and toluene in gas phase cigarette smoke environmental tobacco (ETS) utilizing cryogenic chromatography-mass selective detection (GC-MSD). The MSD operated ion monitoring (SIM) mode. compounds interest eluted less than 15 min. freshly generated mainstream introduced into GC-MSD via a 10-port sampling valve on puff-by-puff basis. This method minimizes ageing smoke. levels 1,3-butadiene ranged...

10.1093/carcin/11.10.1863 article EN Carcinogenesis 1990-01-01

A gas chromatography, negative ion chemical ionization mass spectrometry (GC-NICI-MS) based assay for tobacco-specific nitrosamine adducts of DNA is described. The on the observation that acid hydrolysis from animals treated with nitrosamines releases 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB). HPB and internal standard [4,4-D2]HPB are derivatized pentafluorobenzoyl chloride resulting HPB-pentafluorobenzoate purified by high-performance liquid chromatography prior to GC-NICI-MS analysis. human...

10.1021/tx00021a017 article EN Chemical Research in Toxicology 1991-05-01

Background The present study was conducted among Chinese workers employed in glue- and shoe-making factories who had an average daily personal benzene exposure of 31±26 ppm (mean±SD). metabolites monitored were S-phenylmercapturic acid (S-PMA), trans, trans-muconic (t,t-MA), hydroquinone (HQ), catechol (CAT), 1,2,4-trihydroxybenzene (benzene triol, BT), phenol. Methods S-PMA, t,t-MA, HQ, CAT, BT quantified by HPLC-tandem mass spectrometry. Phenol measured GC-MS. Results Levels (except BT)...

10.1002/(sici)1097-0274(200005)37:5<522::aid-ajim8>3.0.co;2-g article EN American Journal of Industrial Medicine 2000-05-01

To investigate how various levels of exposure affect the metabolic activation pathways benzene in humans and to examine relationship between urinary metabolites other biological markers, we have developed a sensitive specific liquid chromatographic–tandem mass spectrometric assay for simultaneous quantitation S-phenylmercapturic acid (S-PMA) trans,trans-muconic (t,t-MA). The involves spiking urine samples with [13C6]S-PMA [13C6]t,t-MA as internal standards clean up by solid-phase extraction...

10.1093/carcin/20.4.719 article EN Carcinogenesis 1999-04-01

Growth Differentiation Factor 15 (GDF15), a divergent member of the TGF-β superfamily, signals via hindbrain glial-derived neurotrophic factor receptor alpha-like and rearranged during transfection co-receptor (GFRAL-RET) complex. In nonclinical species, GDF15 is potent anorexigen leading to substantial weight loss. MBL949 half-life extended recombinant human dimer.

10.1210/clinem/dgae550 article EN publisher-specific-oa The Journal of Clinical Endocrinology & Metabolism 2024-08-16

The metabolism, pharmacokinetics, and excretion of [<sup>14</sup>C]indacaterol were investigated in healthy male subjects. Although indacaterol is administered to patients via inhalation, the dose this study was orally. This done avoid complications concerns associated with administration a radiolabeled compound inhalation route. submilligram doses made metabolite identification structural elucidation by mass spectrometry especially challenging. In serum, mean <i>t</i><sub>max</sub>,...

10.1124/dmd.112.046151 article EN Drug Metabolism and Disposition 2012-05-30

Tobacco and mainstream smoke of USSR cigarettes were analyzed for carcinogens. The pH values suspensions the tobacco (5.4-5.6) nitrate content tobaccos (0.4-1.7%) as expected flue-cured sun-cured mixtures thereof. nicotine levels cigarette (0.76-0.94%) total alkaloid (0.85-1.08%) relatively low compared with used in Western European US cigarettes. concentrations tobacco-specific N-nitrosamines also (N'-nitrosonornicotine 0.36-0.85 microgram/g) those bright, oriental blended countries (0.3-19...

10.1002/ijc.2910470306 article EN International Journal of Cancer 1991-02-01

Drug-to-antibody ratio (DAR) determination is critical for development of antibody-drug conjugates (ADCs). This work presents a middle-up LC-MS approach DAR analysis using prelabeled capture beads and in-house fabricated slit-plates. Methodology & Results: Cysteine, engineered cysteine disulfide-linked ADCs, each with two different linker payloads, were immunocaptured digested to scFc F(ab')2 fragments. At this point, ADCs analyzed while reduced LC Fd' fragments analysis. Results precise,...

10.4155/bio-2017-0148 article EN Bioanalysis 2017-10-01

2549 Background: Panobinostat (PAN), a hydroxamic acid derivative, is potent pan-deacetylase inhibitor, demonstrating anti-tumor activities in wide variety of preclinical models and showing promising clinical activity. This study elucidates the metabolic elimination pathways PAN using [ 14 C]-PAN. Methods: Four patients with advanced cancer received single oral 20 mg dose C]-PAN (50 μCi). Whole blood, plasma, urine, feces were collected over 7 days. Total radioactivity was measured excreta...

10.1200/jco.2009.27.15_suppl.2549 article EN Journal of Clinical Oncology 2009-05-20

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTAnalyses of steam distillates and aqueous extracts smokeless tobaccoEdmond J. LaVoie, Patricia Tucciarone, Mark Kagan, John D. Adams, Dietrich HoffmannCite this: Agric. Food Chem. 1989, 37, 1, 154–157Publication Date (Print):January 1989Publication History Published online1 May 2002Published inissue 1 January 1989https://pubs.acs.org/doi/10.1021/jf00085a036https://doi.org/10.1021/jf00085a036research-articleACS PublicationsRequest reuse...

10.1021/jf00085a036 article EN Journal of Agricultural and Food Chemistry 1989-01-01

Tropifexor (NVP-LJN452) is a highly potent, selective, nonsteroidal, non-bile acid farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis. Its absorption, metabolism, and excretion were studied after 1-mg oral dose [14C]tropifexor was given to four healthy male subjects. Mass balance achieved with ∼94% administered recovered in excreta through 312-hour collection period. Fecal tropifexor-related radioactivity played major role (∼65% total dose). reached maximum blood...

10.1124/dmd.120.000349 article EN Drug Metabolism and Disposition 2021-05-05

The clinical immunogenicity assessment for complex multidomain biological drugs is challenging due to multiple factors that must be taken into consideration. Here, we describe a strategy overcome bioanalytical challenges in order assess anti-drug antibodies (ADA) novel and unique chemically modified protein therapeutic. A risk-centered approach was adopted evaluate the immunogenic response version of human growth differentiation factor 15 (GDF15) connected an albumin-binding fatty acid via...

10.3389/fimmu.2024.1438251 article EN cc-by Frontiers in Immunology 2024-11-11

Abstract Pradigastat, a diacylglycerol acyltransferase 1 inhibitor, is being developed for the treatment of familial chylomicronemia syndrome. The results two studies that evaluated effect food on oral bioavailability pradigastat using randomized, open‐label, parallel group designs in healthy subjects ( n = 24/treatment/study) are presented. In study 1, single dose 20 mg was administered under fasted condition or with high‐fat meal. 2, 40 low‐ At dose, C max and AUC last increased by 38%...

10.1002/bdd.1958 article EN Biopharmaceutics & Drug Disposition 2015-05-11
Coming Soon ...